Table 1.
Patient characteristics, disease characteristics and prior therapies in patients with multiple myeloma in the in-house FIMM cohort.
| Patient and disease characteristics by disease stagea | |||
|---|---|---|---|
| NDMM (n = 56) | RRMM (n = 78) | Total (N = 134) | |
| Age at diagnosis, years, median (range) | 64.5 (26–84) | 63 (41–81) | 64 (26–84) |
| Sex, female/male, n | 26/30 | 30/48 | 56/78 |
| Cytogenetics, n (%) | |||
| t(11;14) | 16 (28.6) | 14 (17.9) | 30 (22.4) |
| t(4;14) | 7 (12.5) | 18 (23.1) | 25 (18.7) |
| t(14;16) | 1 (1.8) | 2 (2.6) | 3 (2.2) |
| t(14;20) | 0 | 2 (2.6) | 2 (1.5) |
| del(17p) | 5 (8.9) | 20 (25.6) | 25 (18.7) |
| del(13q) | 36 (64.3) | 40 (51.3) | 76 (56.7) |
| 1q gain | 14 (25.0) | 44 (56.4) | 58 (43.3) |
| Missing | 0 | 2 (2.6) | 2 (1.5) |
| ISS, n (%) | |||
| 1 | 13 (23.2) | 16 (20.5) | 29 (21.6) |
| 2 | 26 (46.4) | 22 (28.2) | 48 (35.8) |
| 3 | 10 (17.9) | 16 (20.5) | 26 (19.4) |
| Missing | 7 (12.5) | 24 (30.8) | 31 (23.1) |
| Treatment history of relapsed/refractory patients (N = 78) | |||
| Exposed, relapsed | Exposed, refractory | Not exposed | |
| Prior treatment, n (%) | |||
| Alkylating agents (MEL, CPM) | 61 (78.2) | 15 (19.2) | 2 (2.6) |
| Bortezomib | 43 (55.1) | 26 (33.3) | 9 (11.5) |
| IMiDs | 29 (37.2) | 33 (42.3) | 16 (20.5) |
CPM cyclophosphamide, FIMM Institute for Molecular Medicine Finland, IMiD immunomodulatory imide drug, ISS International Staging System, MEL melphalan, NDMM newly diagnosed multiple myeloma, RRMM relapsed/refractory multiple myeloma.
aIf a patient provided both NDMM and RRMM samples, this patient was included in the NDMM group. If a patient provided samples at multiple relapse stages and the diagnosis sample is missing, then data from the first relapse are included in the table.